

Date: October 10, 2026

To,
The Bombay Stock Exchange
 (BSE Limited)
 Phiroze Jeejeebhoy Towers,
 Dalal Street,
 Mumbai- 400001

Scrip Name: AMWILL HEALTH CARE LIMITED.

Company Scrip Code.: 544353

Re: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") read with SEBI Master Circular no. (Ref: HO/49/14/14(7)2025-CFD-POD2/I/3762/2026) January 30, 2026 ("SEBI Master Circular").

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Grant of licence/regulatory approval for import of FoliColor- Oxidative hair colour.

Dear Sir/Madam,

Pursuant to Regulation 30 read with Para B of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**SEBI Listing Regulations**") and the SEBI Master Circular on compliance with the provisions of the SEBI Listing Regulations, as amended from time to time, we hereby inform you that the Company has obtained a new licence/approval for the import of FoliColor- Oxidative hair colour products into India.

The details required under the SEBI Listing Regulations are given below:

Sr. No.	Particulars	Details
1.	Name of the regulatory/licensing authority	Central Drugs Standard Control Organization (CDSCO)
2.	Type of licence/approval and reference number	Import registration certificate to be issued for import of cosmetics into India; Registration Certificate No. RC/COS-007631
3.	Brief details of the licence/approval	New licence permitting the Company to import FoliColor- Oxidative hair colour products Cosmetic Name along with their brand name: FoliColor - Hair Color Variant Name: Black
4.	Date of grant of licence / date of receipt by the Company	October 09, 2026
5.	Period for which such approval/license is/was valid;	This Registration Certificate shall be in force from 08-Oct-2026 valid upto 07-Oct-2031 unless it is sooner suspended or cancelled under the rules
6.	Impact/relevance of such approval/license to the listed entity	Enables the Company to commence import and commercial sale of the product in India; expected to expand the Company's product portfolio and revenue.



7.	Withdrawal/cancellation or suspension of licence/approval by the regulatory or licensing authority, with reasons for such action, estimated impact (monetary or otherwise) on the listed entity and penalty, if any;	Not Applicable
8.	Whether the licence is a new grant or a renewal/amendment	New grant
9.	Whether the counterparty/supplier is a related party	No
10.	Subsequently, the listed entity shall inform the stock exchange(s), the actual impact (monetary or otherwise) along with corrective actions taken by the listed entity pursuant to the withdrawal, cancellation or suspension of the key license/ approval	Not Applicable

The above information is also being made available on the Company's website www.amwillhealthcare.com , in accordance with Regulation 46 of the SEBI Listing Regulations.

The intimation is being made on [October 10,2026 and 12:57 PM] the information is based on the licence received by the Company on [October 09.2026 and 04:31 PM].

Thanking You.

FOR AMWILL HEALTH CARE LIMITED

ANSHU
ANSHUMAN

Digitally signed by
ANSHU ANSHUMAN
Date: 2026.10.10
12:58:01 +05'30'

Anshu Anshuman

Company Secretary and Compliance Officer

ACS65515

Place: Bangalore